The present invention relates to new polymorphs of LXRβ agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXRβ agonist, as well as methods of treating cancer including administration of a formulation including an LXRβ agonist to a subject in need thereof.本發明係關於LXRβ促效劑之新穎多晶型，其呈現經改良之物理性質。本發明亦關於醫藥組合物，其包括醫藥學上有效量之LXRβ促效劑；以及治療癌症之方法，其包括向有需要之個體投與包括LXRβ促效劑之調配物。
